Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Fisher, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Fisher, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Prevention of macrovascular complications

M. Fisher*

Glasgow Royal Infirmary, Glasgow, Scotland

* Dr Miles Fisher, Consultant Physician, Glasgow Royal Infirmary, Castle Street, Glasgow G4 OSF, Scotland.

Abstract

The cardiovascular burden of diabetes is well established. Reduction in this burden requires a multifactorial approach, encompassing control of glycaemia, reduction in traditional cardiovascular risk factors (hypertension, hyperlipidaemia), use of antiplatelet agents and angiotensin-converting enzyme inhibitors, and aggressive treatment of coexisting cardiovascular disease. Metformin is the drug of first choice for blood glucose control in most patients, and the newer thiazolidinediones have some additional effects on other aspects of the metabolic syndrome that could provide extended cardiovascular benefit. Several different groups of drugs are of proven benefit in reducing blood pressure, and multiple agents may be required. Statins are of proven benefit for both primary and secondary prevention, but there is less hard evidence available on the use of fibrates in people with diabetes. Use of these multiple potential therapies is included in several guidelines for reducing cardiovascular risk in people with diabetes, but compliance and adherence is a problem.

Key Words: Blood glucose control • cardiovascular risk • diabetes mellitus • hyperlipidaemia • hypertension


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.